Supplemental material for the publication "Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity"
Type of the data | Text | |
Type of the data | Image | |
Total size of the dataset | 1126236 | |
Author | Prengemann, Lea | |
Author | Stein, Robert | |
Author | Gausche, Ruth | |
Author | Beger, Christoph | |
Author | Vogel, Mandy | |
Author | Wenzel, Eric | |
Author | Stoltze, Anette | |
Author | Kiess, Wieland | |
Author | Pfäffle, Roland | |
Author | Körner, Antje | |
Upload date | 2025-12-02T13:30:45Z | |
Publication date | 2025-12-02T13:30:45Z | |
Data of data creation | 2025-11-27 | |
Publication date | 2025-12-02 | |
Abstract of the dataset | Background and Objectives: Being born small for gestational age (SGA) and growth hormone (GH) treatment are linked to disturbed glucose-insulin metabolism. We investigated how GH treatment affects glucose-insulin metabolism in children born SGA compared to children with isolated growth-hormone deficiency (iGHD), obesity and lean controls. Methods: We analyzed glucose-insulin metabolism indices derived from OGTTs (Matsuda index, AUC insulin) and fasting parameters (fasting glucose, HOMA-IR) in 134 SGA patients without catch-up growth (CUG) receiving GH therapy (SGA-GHT), 27 untreated SGA patients with catch-up growth (SGA-CUG), 308 iGHD patients under GH treatment, 427 children with obesity and 356 lean controls. We adjusted for sex, age and BMI through matching and multivariable regression. Results: Treatment-naïve SGA-GHT patients were more insulin-resistant than iGHD patients (higher insulin AUC (p=0.002) and HOMA-IR (p<0.001), lower Matsuda index (p<0.001)) with levels approaching those of the obesity cohort. Under GH therapy, HbA1c was higher in SGA-GHT and iGHD patients (5.26%±0.35 vs. 5.25%±0.25) than in lean controls (5.09%±0.27). Insulin resistance in SGA-GHT patients approached levels seen in obesity. The prevalence of prediabetes was highest in SGA-GHT children (11.11%) compared to those with iGHD (1.59%) or obesity (3.13%). After stopping GH therapy, SGA-GHT patients retained elevated markers of prediabetes (4.65%) and insulin resistance compared to controls and iGHD patients, similar to children with obesity (6.38%). No overt type 2 diabetes was observed. Conclusion: SGA patients have an impaired glucose-insulin metabolism similar to that of children with obesity, which worsens under GH therapy. Close metabolic monitoring of GH-treated SGA patients is recommended. | |
Public reference to this page | https://opara.zih.tu-dresden.de/handle/123456789/1870 | |
Public reference to this page | https://doi.org/10.25532/OPARA-1027 | |
Publisher | Universität Leipzig | |
Licence | Attribution-NonCommercial 4.0 International | en |
URI of the licence text | http://creativecommons.org/licenses/by-nc/4.0/ | |
Specification of the discipline(s) | 2::22 | |
Title of the dataset | Supplemental material for the publication "Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity" | |
Funding Acknowledgement | This work was supported by the German Research Foundation for the Clinical Research Center “Obesity Mechanisms” (grant CRC1052, project number 209933838, subproject C05). LIFE Child is supported by the Free State of Saxony as per the budget approved by the state parliament and Leipzig University’s Medical Faculty. Moreover, the project was funded by the Federal Ministry of Research, Technology and Space (Bundesministerium für Forschung, Technologie und Raumfahrt; BMFTR) as part of the German Center for Child and Adolescent Health (DZKJ) under the funding code 01GL2405A. CrescNet is supported by unrestricted grants from Hexal, NovoNordisk and Biomarin. Furthermore, LP, RS, EW and AK acknowledges support by the German Diabetes Association (DDG). RS and EW are supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG); project number 493646873 – MD-LEICS. RS also acknowledges financial support by the Faculty of Medicine, University Leipzig (“Nachwuchsförderprogramm”). The funding organization had no role in the study design, data collection, analysis, or interpretation of the results. |
Collections
